# Tumour-stroma ratio

Source: https://onco.cc/terms/tumor-stroma-ratio/  
OnCo record `tumor-stroma-ratio` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The tumour-stroma ratio describes the amount of supporting tissue in a defined tumour region; its method and cutoff must stay with the result.

## Summary

Tumour-stroma assessment on routine histology describes tissue composition. It differs from stromal TIL assessment, which describes the inflammatory infiltrate within eligible stroma. Prognostic associations do not by themselves establish which treatment should be chosen.

## Fields

- Kind: Term
- Last checked: 2026-11-10

## Notes

- UNITED prospectively assessed the ratio in stage II or III colon cancer: 1,388 eligible patients from 27 centres. Stroma-high meant more than 50% stroma, while 50% or below was stroma-low. Three-year disease-free survival was 70% versus 83%; adjusted hazard ratio 1.49 (95% confidence interval 1.17 to 1.90). Overall survival did not differ significantly. These findings describe that colon-cancer cohort.
- The 124-person retrospective triple-negative breast cancer study used a different boundary: at least 50% was stroma-high and less than 50% was stroma-low. It reported observer agreement kappa 0.74. Kappa summarises agreement after allowing for chance; this value belongs to those investigators and cases. Do not transfer the boundary from one protocol to another without checking it. Neither study establishes an individual treatment benefit from choosing a drug according to this score.
- The cited colon visual TSR protocol selects a stroma-rich eligible invasive-tumour region at low power, then estimates stroma in a field at a 10-times objective with tumour visible at all four edges, in 10 percentage-point steps. UNITED used more than 50% as stroma-high. This selected-field measurement is not an average of the entire slide, a tumour-cell proportion or a residual tumour-bed cellularity score.
- Fictional untreated tumour fields contain 30%, 40% and 70% stroma. Under the stroma-rich-field rule, the score is 70%, stroma-high, provided the field is eligible. The average is about 47% and answers a different question. Supporting tissue can contain many or few lymphocytes; stroma-high does not establish immune exclusion.
- In the 124-person retrospective TNBC cohort, five-year relapse-free rates were 85% for stroma-low and 45% for stroma-high; adjusted relapse hazard ratio 2.39 (95% confidence interval 1.07 to 5.29). In the 574-person early breast cancer series, the TNBC subgroup had five-year relapse-free rates of 81% for stroma-poor and 56% for stroma-rich tumours. A separate node-negative premenopausal cohort validated the prognostic direction. These are cohort associations, not personal forecasts.
- The 2026 automated analysis used 853 stage II or III colon cancers from UNITED without neoadjuvant therapy. It segmented 11 tissue classes and calculated stroma/(stroma + epithelial tumour), using a 1-mm region and a derived 77% cutoff. This is a different method from a visually chosen 10-times field with a 50% cutoff; its threshold cannot be imported into the visual method.
- The breast review identified a need for prospective validation. UNITED provides prospective prognostic evidence in colon cancer, while the cited breast studies are retrospective. The cited analyses do not establish a randomised treatment-by-score interaction that chooses a drug. Untreated cohorts do not validate transfer to post-neoadjuvant fibrosis. The cited studies alone do not establish current guideline adoption.
- For the cited visual TSR protocol, record the H&E specimen and whether treatment preceded collection, select the eligible most stroma-rich field at a 10-times objective with tumour on all four sides, and estimate the stromal percentage in 10 percentage-point steps. State the observer method and protocol-specific high/low boundary. Software requires its own definition and cutoff. Field choice, necrosis, mucin and post-treatment fibrosis can change interpretation; this selected-field score is not interchangeable with a whole-slide average.

## Sources

- van Pelt et al., colon TSR scoring procedure, 2018: https://pubmed.ncbi.nlm.nih.gov/30030621/
- Polack et al., UNITED, 2024: https://pubmed.ncbi.nlm.nih.gov/38613913/
- Moorman et al., TNBC cohort, 2012: https://pubmed.ncbi.nlm.nih.gov/22264965/
- de Kruijf et al., breast TSR cohort, 2011: https://pubmed.ncbi.nlm.nih.gov/20361254/
- Dekker et al., node-negative validation, 2013: https://pubmed.ncbi.nlm.nih.gov/23709090/
- Kramer et al., breast evidence review, 2019 print: https://pubmed.ncbi.nlm.nih.gov/30302588/
- Heilijgers et al., automated UNITED analysis, 2026: https://pubmed.ncbi.nlm.nih.gov/41468683/

## Connected records

- terms: [H&E staining (haematoxylin and eosin)](https://onco.cc/terms/h-and-e-staining/), [Tumour purity](https://onco.cc/terms/tumour-purity/), [Tumour-bed cellularity](https://onco.cc/terms/tumor-bed-cellularity/), [Tumour-infiltrating lymphocytes (TILs)](https://onco.cc/terms/tils/)

---
JSON: https://onco.cc/api/v1/entities/tumor-stroma-ratio.json